← TheStudyFix Medical LibraryFlashcards
TheStudyFix logoCreated by TheStudyFix

Induction — Infection & Tropical

47 diseases · 18 criteria · structured C/P · Inves · Mng

C/P — Clinical Presentation
Inves — Investigations
Mng — Management
Special — Pathognomonic / disease-unique

Hospital-Acquired & Surgical Infection

21 entries
1

Surgical Site Infection (SSI)

C/P
  • Erythematous, oedematous, tender wound; bacterial count >100,000 organisms/g tissue
  • Most common early post-op fever cause traditionally blamed on atelectasis; SSIs typically present later
  • 20% of surgical patients acquire nosocomial infections; SSI = 3rd most common form
  • 1–12% complication rate across all operations
  • Operation-specific rates: inguinal herniorrhaphy 2%; cholecystectomy 3%; appendectomy 5%; thoracotomy 6%; colectomy 12%
  • Early infection (<12h): fever to 39°C, foul-smelling serous discharge, particularly painful wound, ± crepitus — red flag for clostridial infection
  • Organ/space SSI may remain occult or present only with systemic signs — fever, ileus, shock (mimics incisional SSI)
Inves
  • Septic screen: blood cultures, FBC + CRP, MSU, aspiration of pus (preferred to swab), CXR
  • Gram stain of the serous discharge for gram-positive rods — confirms or excludes clostridial infection
Mng
  • Source control (incision/drainage)
  • Antibiotics
  • Remove/change lines
  • Infection control measures
  • Antibiotic prophylaxis: give within 1h before incision (2h for vancomycin/fluoroquinolone), redose per drug half-life, stop within 24h (48h for cardiac surgery); clindamycin if β-lactam allergy
  • Superficial SSI: open the incision + local wound care; antibiotics only if erythema extends beyond the wound margin or systemic signs
Special
  • Endogenous source (primary): patient's own flora; e.g., perforated appendix
  • Exogenous source (secondary/HAI): operating theatre or ward
  • Most common bacterial source in groin hernia repair = patient's skin
  • Highest predisposed procedures = GI (especially colon opened)
  • Risk of death 4× higher; cost $12,000–30,000 per infection; LOS +3–7 days
  • Bacterial translocation can occur in as little as 30 minutes when gut barrier breached
  • Timing criterion: must occur within 30 days of surgery — or within 1 year if implanted foreign material is present
  • Depth classification: superficial incisional (skin/subcutaneous), deep incisional (fascial/muscle layers), organ/space (any structure opened or manipulated during the operation)
  • Wound contamination classes (infection rate): I Clean 2.1%, II Clean-contaminated 3.3%, III Contaminated 6.4%, IV Dirty-infected 7.1%
  • NNIS risk index: ASA score >2; class III/IV wound; operative duration >75th percentile for that procedure
  • Foreign material drops the infective inoculum to only 100 bacteria (vs 1 million on violated skin, 8 million on intact skin)
physiology · background · low-yield
Epidemiology/Risk
  • Cigarette smoking is the leading preventable patient factor — more than triples incisional wound breakdown risk (0.6%→3.6% in clean procedures)
  • Perioperative normothermia markedly reduces SSI: 19% wound infection in hypothermic vs 6% normothermic colorectal patients; blood transfusion increases risk (immunosuppression)
Mechanism
  • The 'decisive period': host inflammatory/humoral/cellular defenses take up to 4h to mobilise — antibiotic tissue levels must exceed MIC90 before incision or prophylaxis is ineffective
Background
  • Wound irrigation: tap water reduces bacterial load; alcohol, sodium hypochlorite and hydrogen peroxide are toxic to tissue/fibroblasts — 'put nothing into a wound you would not put in your eye'
  • Preventive measures: hair removal with clippers/depilatory not razors; intranasal mupirocin for S. aureus nasal carriers; oral + IV antibiotics superior to IV alone in elective colon surgery
  • Vacuum-assisted closure (VAC) optimises blood flow, reduces oedema and aspirates fluid — but can mask wound sepsis (odour/drainage hidden by suction apparatus)
2

Ventilator-Associated Pneumonia (VAP) / HAP / HCAP

C/P
  • VAP: pneumonia occurring 48–72h after endotracheal intubation
  • Most common ICU infection for surgical/trauma patients
  • Early-onset VAP (<5 days): trauma patients prone; aspiration of gastric contents
  • Late-onset VAP (≥5 days): MDR pathogens
Inves
  • Culture-guided
  • Cover gram-positive cocci more common in diabetics, head trauma, ICU
Mng
  • Early broad-spectrum antibiotics in adequate doses; deescalate based on culture
  • Delayed appropriate therapy → increased mortality
  • Empirical (immunocompetent, no MDR risk): ceftriaxone, fluoroquinolone, ampicillin/sulbactam, ertapenem
  • MRSA: linezolid (with emerging linezolid resistance)
  • P. aeruginosa: some isolates only susceptible to polymyxin B
Special
  • VAP partly iatrogenic
  • Early-onset organisms: methicillin-sensitive S. aureus, Streptococcus pneumoniae, Haemophilus influenzae (usually sensitive)
  • Late-onset MDR organisms: MRSA, Pseudomonas aeruginosa, Acinetobacter spp.
  • Common gram-negatives: P. aeruginosa, E. coli, K. pneumoniae, Acinetobacter
  • Anaerobic infection follows aspiration in non-intubated patients; rare in VAP
  • Candida in immunocompetent patient = colonisation, not infection
  • MDR risk factors: hospitalisation ≥5 days; antimicrobials/hospitalisation in prior 90d; nursing home; home infusion; chronic dialysis within 30d; home wound care; family member with MDR pathogen; immunosuppression
  • Pneumonia is 2nd most common nosocomial infection after UTI
  • Early-onset VAP carries a better prognosis than late-onset
  • P. aeruginosa is the most common gram-negative pathogen in MDR HAP/VAP; some isolates susceptible only to polymyxin B
physiology · background · low-yield
Epidemiology/Risk
  • S. aureus accounts for ~40% of VAP episodes and most cases of nosocomial pneumonia
Microbiology
  • Pathogens are a wide spectrum, often polymicrobial (especially in ARDS patients)
Mechanism
  • Broad-spectrum antibiotics replace upper-respiratory-tract commensals with Klebsiella, which then causes VAP
3

Post-operative UTI (Catheter-associated)

C/P
  • Most patients harbour infected urine by 5–7 days after surgery (longer catheter = more likely)
  • One of the "4 Ws" of post-op fever ("Water")
  • Urinary catheter left >2 weeks often causes infection; catheters beyond a few days need increased UTI surveillance
Inves
  • Urinalysis: WBC
  • Urine culture: >100,000 bacteria/ml
Mng
  • Treat per culture
  • Catheter removal/change
Special
  • Bacteria crawl up the outside of the urethral catheter
  • Urological instrumentation accelerates the process
  • UTI = most common nosocomial infection overall (35% of HAI in pie chart)
4

Intra-abdominal Infections (IAI)

C/P
  • Uncomplicated (uIAI): contained within a single organ; no GI perforation; rarely causes serious illness
  • Complicated (cIAI): extends beyond source organ into peritoneal cavity via perforated viscus → SIRS
  • Contained spread → abscess; uncontained → diffuse peritonitis → higher mortality, needs urgent celiotomy
  • CA-IAI (community-acquired): lower mortality/morbidity
  • HA-IAI (healthcare-associated): higher mortality/morbidity; resistant pathogens; portends particularly poor prognosis
  • Occult (usually intra-abdominal) abscess is a classic cause of late post-op fever (~2 weeks)
  • Typically polymicrobial gut flora — Enterobacteriaceae (esp. E. coli), anaerobes (Bacteroides fragilis) and enterococci; empirical cover must include anaerobes + gram-negatives
Inves
  • Imaging to identify source; cultures
Mng
  • CA-IAI: narrow-spectrum, pathogen-specific antimicrobial
  • HA-IAI / high-risk cIAI: broad-spectrum empirical antimicrobial (MDR risk)
  • Source control (e.g., percutaneous drain by interventional radiology for subphrenic abscess; surgical for perforated viscus)
Special
  • Delayed diagnosis triad in HA-IAI: low index of suspicion, poor underlying health, altered sensorium
  • Healthcare-associated nonpostoperative IAI (e.g., acute acalculous/non-calcular cholecystitis in a hospitalised patient) — portends a particularly poor prognosis
5

C. difficile Colitis

C/P
  • Frequent stools, abdominal pain, somnolence after recent broad-spectrum antibiotic course
  • Can progress to septic shock with cool skin, hypotension, elevated lactate
Inves
  • Stool testing (implied — deck doesn't enumerate specific tests)
Mng
  • Per institutional protocol; source control
  • Hand hygiene = soap and water — alcohol gel/hand rub is ineffective against C. difficile spores; use contact isolation
Special
  • Replaces colonic commensals after broad-spectrum antibiotics
  • "Potentially life-threatening diarrhoea in postoperative patients"
  • Classic context: recent antibiotic course (e.g., diverticulitis treatment)
physiology · background · low-yield
Mechanism
  • Normal gut flora ordinarily discourages C. difficile colonisation; broad-spectrum antibiotics clear commensals and allow overgrowth (also occurs in community and nosocomial settings)
6

Necrotising Soft Tissue Infections (NSTI)

Inves
  • Simpler 'Wall' model: admission WBC <15,400/uL and/or serum Na >135 mEq/L gives NPV 99% and 90% sensitivity for NSTI (distinct from the LRINEC score)
  • Low serum Na theorised to reflect SIADH or adrenal insufficiency
Special
  • Incidence 0.40 per 100,000 in adults vs 0.08 per 100,000 in paediatrics per year; affects males and females equally
  • Streptococcus is the #1 isolated organism (then Staphylococcus); Clostridium is now a RARE cause due to improved sanitation; of monomicrobial NSTIs, Klebsiella, S. pyogenes and C. perfringens are most common
  • Obesity paradox: one study demonstrated a PROTECTIVE effect of obesity on in-hospital mortality in NSTI
  • Paediatric NSTI: predisposing factors consistently include varicella lesions and intramuscular injections; more likely monomicrobial secondary to Streptococcus pyogenes
  • Type 2 diabetics presenting in diabetic ketoacidosis have longer hospital stays and higher mortality; poor glycaemic control correlates with extent of disease and poor outcomes
7

Clostridial Myonecrosis / Gas Gangrene

Mng
  • Antibiotic differs from necrotizing fasciitis: high-dose penicillin for clostridial infection (vs broad-spectrum for necrotizing fasciitis)
  • Both need fluid/electrolyte resuscitation plus aggressive debridement
Special
  • Clostridial infection involves underlying MUSCLE -> myonecrosis / gas gangrene; non-clostridial NSTI involves the subcutaneous fascia
8

Anthrax (Bacillus anthracis)

Special
  • Category-A biologic warfare agent selected for inhalational (mass-exposure) spread
9

Plague (Yersinia pestis)

Special
  • Named biologic warfare agent (Yersinia pestis)
10

Smallpox

Special
  • Named biologic warfare agent
11

Tularemia (Francisella tularensis)

Special
  • Named biologic warfare agent (Francisella tularensis)
12

Wound dehiscence & evisceration

C/P
  • Dehiscence = partial/total disruption of any/all layers of an operative wound; evisceration = rupture of abdominal wall + extrusion of viscera
  • Timing: most common 5th-10th postop day (wound strength at its minimum)
  • First sign = serosanguineous leak; tearing/popping on coughing
  • Healing ridge normally ~0.5 cm each side within 1 week; its absence predicts breakdown
Mng
  • Dehiscence: elective reclosure if no infection; otherwise heal by second intention
  • Evisceration = emergency (mortality 10-20%); cover with moist towels, prompt closure
Special
  • Adequacy of closure is MOST important; infection is the agent in >half of dehisced wounds
  • Predisposing: age >60, obesity, raised intra-abdominal pressure, malnutrition, renal/hepatic insufficiency, DM, corticosteroids, cytotoxics, prior irradiation, infection
13

Vacuum-assisted closure (VAC) / negative pressure wound therapy

Mng
  • Uses: sternal infection after cardiac surgery, abdominal wall dehiscence, complex perineal wounds, securing skin grafts
Special
  • First appraised in a porcine model in 1997
  • Optimizes blood flow, decreases oedema, aspirates fluid (facilitates bacterial clearance); negative pressure promotes wound contraction + may increase cellular proliferation
  • Odour/drainage clues to wound sepsis are hidden by the suction apparatus - evaluate the wound if sepsis signs appear with an unidentified source
14

Catheter-related bloodstream infection / bacteraemia

Mng
  • Prevention: full sterile barrier precautions, strict catheter-care protocols, prompt removal when no longer needed
Special
  • One of the 4 main HAI groups (mostly related to indwelling vascular catheters)
  • IV catheter placed in a central vein, in place >3-5 days, or used for blood sampling
15

Fever - pathophysiology & antipyresis

C/P
  • Normal core temp 36-38 C (cool ~36 C before rising in the morning, hot ~38 C at night)
  • Fever = pathologic systemic inflammatory state; core temp >38 C but rarely >40 C
Mng
  • Antipyresis: aspirin / paracetamol / ibuprofen = COX inhibitors blocking prostaglandin E2 formation in the hypothalamus
Special
  • Macrophages activated by bacteria/endotoxin release IL-1, TNF and interferon, which reset the hypothalamic thermoregulatory centre
  • Sterile atelectasis (early postop collapse is typically not infected) has nothing to do with fever; a total pneumothorax (large atelectasis) does NOT cause fever
16

Sepsis / Septic Shock - hospital aetiology

Special
  • Aetiology in hospitalised adults has shifted from predominantly gram-negative nosocomial (E. coli, Klebsiella, Enterobacter, Pseudomonas aeruginosa) to gram-positive (S. aureus, S. pneumoniae, S. pyogenes)
  • Gram-positive sepsis incidence up 26.3% per year since the early 1980s; MDR pathogens (esp S. aureus) now >half of all sepsis cases; S. aureus alone = 40% of VAP episodes + most nosocomial pneumonia
  • Group B Streptococcus = leading cause of neonatal sepsis in the United States
17

Surgical Site Infection (SSI) - risk factors & prevention

Mng
  • Smoking = probably the leading PREVENTABLE patient factor; >triples incisional breakdown, increased SSIs sixfold (0.6% to 3.6%) in clean procedures; decreases wound blood flow/O2 delivery, impedes all stages of healing
  • Surgical scrub: classic = 3-min brushing with povidone-iodine or chlorhexidine gluconate (high noncompliance); simpler 1-min non-antiseptic soap wash + aqueous alcoholic hand-rub gives better compliance with comparable SSI rates
  • Hair removal: NO hair removal preferred; if removed use clippers or depilatory immediately before surgery - razors are not to be used
  • Normothermia: colorectal surgery 19% (hypothermic) vs 6% (kept normothermic); clean surgery (breast/varicose vein/hernia) 5% (warmed 30 min pre-op) vs 14%; target core temp 96.8-100.4 F within first hour after leaving OR
  • Glucose control (cardiac surgery): keep blood glucose <200 mg/dL for first 2 postop days (measured closest to 6am on days 1 and 2); continuous-infusion control decreases sternal wound infection in diabetics; risk = hypoglycaemia
  • Other prophylactic routes: intranasal mupirocin ointment in S. aureus nasal carriers may decrease nosocomial + SSI; in elective colon surgery oral + IV antibiotics are superior to IV alone
  • Wound irrigation: tap water decreases bacterial load + promotes healing; alcohol toxic to tissues; Dakin solution (sodium hypochlorite) + hydrogen peroxide kill fibroblasts and slow epithelialisation ('put nothing in a wound you would not put in your eye')
  • Blood transfusion increases wound-infection risk (immunosuppressive effect)
Special
  • The 'decisive period' - acute inflammatory/humoral/cellular defences take up to 4 hours to mobilise; invading bacteria become established in this window, after which preventive strategies are ineffective; tissue levels must exceed the MIC90 of likely pathogens
  • Each mL of human saliva contains 100,000,000 aerobic + anaerobic, gram-positive + gram-negative bacteria; all human bites are contaminated, whereas animal bites are typically less contaminated
  • SSI risk factors organised into 5 categories: patient, local, microbial, environmental, treatment
  • Adequacy of regional blood supply is predictive - evidenced by the low infection rate of facial wounds
  • Endogenous source: large bowel is a reservoir for bacteria + endotoxin; breach (splanchnic ischaemia, impoverished luminal nutrition of enterocytes, or altered flora) allows translocation into the portal circulation in as little as 30 min; if Kupffer cells are also impaired, bacteria/endotoxin reach the systemic circulation (may explain hepatorenal syndrome in jaundiced surgical patients + the ~30% who develop organ dysfunction with no obvious infection source)
18

C. difficile colitis / Pseudomembranous colitis

Mng
  • Oral metronidazole first-line; oral vancomycin second-line
Special
  • Alcohol gel hand cleansers are ineffective against C. difficile spores - require cleansing with soap and water
19

Bacterial toxins - exotoxin vs endotoxin

Special
  • General rule: gram-positive organisms produce EXOTOXINS; gram-negative organisms have ENDOTOXINS
  • B. fragilis (gram-negative) produces no exotoxin and has defective lipopolysaccharide + lipid A
  • C. perfringens produces a heat-labile enterotoxin causing watery diarrhoea
  • S. aureus produces haemolysin + leukocidin (damage plasma membranes) and exfoliatin (cleaves desmosomes)
20

Antibiotic pharmacology - mechanisms

Special
  • Beta-lactams (penicillins, cephalosporins, monobactams, carbapenems) inhibit the final step of cell-wall synthesis via transpeptidases / penicillin-binding proteins
  • Tazobactam / sulbactam / clavulanic acid bind beta-lactamases (Zosyn, Augmentin)
  • Metronidazole inhibits nucleic-acid synthesis, requires reduction to its active form (anaerobes only), has a disulfiram-like reaction (no alcohol), is liver-cleared, and prolonged use causes peripheral neuropathy
  • Aminoglycosides + tetracyclines inhibit the 30S ribosome; linezolid / macrolides / chloramphenicol inhibit the 50S; clindamycin (lincosamide) interferes with the amino-acyl-tRNA complex
21

Nosocomial infection (general)

Special
  • Increased risk: underlying chronic disease, alteration in host defences, prolonged hospital stay, presence of invasive catheters/monitoring devices
  • Pulmonary, urinary tract, GI and wound infections predominate

Malaria & Protozoal

4 entries
22

Malaria

C/P
  • Initial symptoms non-specific: tachycardia, tachypnea, chills, malaise, fatigue, diaphoresis, headache, cough, anorexia, nausea, vomiting, abdominal pain, diarrhoea, arthralgia, myalgia
  • Physical: anaemia + palpable spleen
  • Mild jaundice may develop in uncomplicated falciparum
  • Febrile paroxysms at irregular intervals; temp can rise >40°C with tachycardia/delirium; cyclic 2–3 days
  • Febrile convulsions in children (any species); generalised seizures associated with falciparum (may herald cerebral malaria)
  • Severe malaria: altered consciousness ± seizures; respiratory distress or ARDS; circulatory collapse; metabolic acidosis; renal failure with haemoglobinuria ("blackwater fever"); hepatic failure; coagulopathy ± DIC; severe anaemia or massive intravascular haemolysis; hypoglycaemia
  • Pallor, petechiae, jaundice, hepatomegaly, splenomegaly (splenic rupture described)
  • Cerebral malaria: encephalopathy with impaired consciousness, delirium, ± seizures; focal neurological signs unusual; onset gradual or sudden following a convulsion
Inves
  • Suspect in any febrile illness with exposure to endemic region
  • Light microscopy (standard tool): Giemsa-stained blood smears
    • Thin smear: erythrocyte morphology preserved; parasites visible within RBCs; for species ID + parasite density
    • Thick smear: mechanical lysis of RBCs; reviews large blood quantity; for presence/absence screening + density estimation
  • Rapid diagnostic tests (RDTs): detect parasite antigens (HRP2, pLDH, aldolase); 15–20 min; resource-limited settings; qualitative only; can distinguish P. falciparum vs P. vivax depending on antigen
  • PCR (molecular): gold standard in efficacy studies; reference labs only
  • Uncomplicated parasitemia: <5,000 parasites/µL (<0.1% RBCs); anaemia, thrombocytopenia, elevated transaminases, mild coagulopathy, raised BUN + creatinine
  • Severe: parasitemia ≥4–10%; increasing parasitemia → increasing severity
  • Cerebral malaria: CSF normal or slightly elevated protein/cell count; retinal haemorrhages 30–40% (pupillary dilation + indirect ophthalmoscopy)
  • Thrombocytopenia associated with increased risk of death (falciparum or vivax), especially with severe anaemia
Mng
  • Inform patients of recrudescence; report to state health department
  • Identify chloroquine-sensitive vs resistant area
  • Uncomplicated, chloroquine sensitive: chloroquine monotherapy
  • Uncomplicated, chloroquine resistant: combination of two agents (ACTs)
  • Hospitalisation indications: clinical observation for tolerance; young children; immunocompromised; no acquired immunity (travellers); hyperparasitemia 4–10% without severe signs
  • Severe malaria — parenteral artemisinin:
    • Artesunate IV/IM 2.4 mg/kg at 0, 12, 24, 48h
    • OR artemether IM 3.2 mg/kg stat then 1.6 mg/kg OD
    • Follow-up: ACT + primaquine (0.75 mg/kg on day 2)
    • If artemisinin unavailable: quinine salt 20 mg/kg infusion then 10 mg/kg Q8H; follow-up quinine 10 mg/kg Q8H PLUS doxycycline 100 mg OD OR clindamycin 10 mg/kg BD × 7 days (clindamycin in pregnancy / child <8)
Traveller Chemoprevention
  • Low risk/sporadic: mosquito avoidance only
  • Chloroquine-resistant P. falciparum: mosquito avoidance + atovaquone-proguanil OR mefloquine OR doxycycline OR tafenoquine
  • Chloroquine-sensitive P. falciparum: chloroquine OR atovaquone-proguanil/tafenoquine (mefloquine, doxycycline also effective)
  • P. vivax dominant (Mexico / Central America): primaquine OR tafenoquine (check G6PD); chloroquine also effective
  • Long-term use evidence supports atovaquone-proguanil, chloroquine, doxycycline, mefloquine for up to 2 years
  • Timing: start before travel, continue during, and for a period after departure
  • If parasite-based diagnosis unavailable and suspicion high for P. falciparum: reasonable to begin empiric therapy to prevent severe disease
Special
  • Plasmodium parasite; female Anopheles mosquito vector (bites dusk–dawn)
  • P. falciparum = largest burden (sub-Saharan Africa, New Guinea, Hispaniola)
  • P. vivax: Americas, western Pacific
  • Lifecycle: bite → sporozoites travel to liver → mature → enter blood → infect RBCs (multiply 48–72h) → burst at ~2 weeks releasing merozoites (cause fever) → cyclic 2–3 days
  • Severe pathophysiology: cytoadherence of parasitised (+ non-parasitised) RBCs to small vessels → micro-infarcts, capillary leakage, organ dysfunction
  • Cerebral malaria untreated = almost universally fatal; treated mortality 15–20%
  • Risk factors for cerebral malaria: extremes of age, pregnancy, poor nutrition, HIV, genetics, splenectomy
  • Differentials:
    • Dengue: myalgia more severe ("breakbone fever") — serology
    • Chikungunya: dengue-like but milder/self-limiting with rash — serology
    • Meningitis: no neck stiffness/photophobia in malaria; malaria has no rash
    • Typhoid: bradycardia, abdominal pain, rose spots — stool/blood culture
    • Leptospirosis: more severe myalgia + petechial haemorrhages (rare in malaria)
    • Viral haemorrhagic fever: petechial haemorrhages common
  • Pneumonia: fever, cough, dyspnoea, sputum production; patients may have intercostal retractions and other signs of laboured breathing
  • Sepsis (bacteraemia): requires blood culture
physiology · background · low-yield
Epidemiology/Risk
  • WHO 2018: 219 million cases worldwide (down from 239M in 2010); most in African region (92%), then SE Asia (5%), Eastern Mediterranean (2%); ~95 countries with ongoing transmission; >85% of deaths in sub-Saharan Africa
  • Anaemia is common in young children in endemic areas (often multifactorial)
Microbiology
  • Light microscopy also diagnoses other blood parasites: filariasis, trypanosomiasis, babesiosis
Other
  • Clinical diagnosis: no pathognomonic clinical signs; frequently incorrect (confirmed parasitemia in febrile patients in sub-Saharan Africa often <50%)
  • Chemoprevention: if multiple destinations, select a single agent effective for all
23

Malaria - Life Cycle & Vector

Special
  • Life cycle: infected Anopheles bites - sporozoites into bloodstream - migrate to liver, invade hepatocytes, divide into multinucleated schizonts (pre-erythrocytic/exoerythrocytic stage) - schizonts rupture releasing merozoites into circulation - invade RBCs - within RBCs mature ring form to trophozoite to multinucleated schizont (erythrocytic stage) - some merozoites become male/female gametocytes ingested by mosquito, mature in midgut, sporozoites develop and migrate to salivary glands
  • Hypnozoites: quiescent liver stage existing ONLY in P. vivax and P. ovale; cause no clinical symptoms but can reactivate to cause late-onset/relapsed disease up to many months after initial infection; primaquine (and tafenoquine) is active against hypnozoites
  • Drug stage-activity: hepatic (pre-erythrocytic) schizonts targeted by atovaquone-proguanil and primaquine; blood-stage schizonticides = artemisinins, atovaquone-proguanil, doxycycline, mefloquine, chloroquine; primaquine acts on blood-stage schizonts of P. vivax but NOT P. falciparum
  • Anopheline (malaria) mosquito rests with head, thorax and abdomen in a straight line at an acute angle to the surface; Culicine mosquito rests with head and body angled and abdomen directed back toward the surface
  • Timeline: parasites multiply within RBCs; after ~2 weeks incubation infected cells burst and release merozoites (responsible for the fever); symptoms recur in cycles lasting 2-3 days at a time
24

Cerebral Malaria

C/P
  • Encephalopathy: impaired consciousness, delirium and/or seizures; focal neurologic signs unusual
  • Onset gradual or sudden following a convulsion; severity depends on parasite virulence, host immune response, and time between symptom onset and start of therapy
  • Risk factors: age (children and older adults), pregnancy, poor nutritional status, HIV infection, host genetic susceptibility, history of splenectomy
  • Can progress rapidly to coma and death; untreated almost universally fatal; with treatment mortality 15-20%
Inves
  • CSF examination may be normal or show slightly elevated total protein level and cell count
  • Retinal hemorrhages seen in 30-40% of cases (detected via pupillary dilation and indirect ophthalmoscopy)
25

Malaria - Traveler's Chemoprophylaxis

Mng
  • Selection tailored to individual itinerary; for multi-destination trips a single agent effective for the entire exposure may be simplest
  • Sporadic / very low-risk destinations: mosquito avoidance only, no chemoprophylaxis needed
  • Chloroquine-resistant P. falciparum areas: mosquito avoidance + chemoprophylaxis with atovaquone-proguanil, mefloquine, doxycycline OR tafenoquine (all four highly efficacious)
  • Chloroquine-sensitive P. falciparum areas: chloroquine (short-term travelers may prefer shorter course of atovaquone-proguanil or tafenoquine; mefloquine and doxycycline also effective)
  • P. vivax-predominant areas (e.g. malaria-endemic Mexico and Central America): primaquine or tafenoquine ONLY in absence of G6PD deficiency; chloroquine also effective
  • Timing: start before travel, continue regularly during exposure, and for a period after departure from the endemic area
  • Safe for long-term use up to 2 years: atovaquone-proguanil, chloroquine, doxycycline, mefloquine

Brucellosis

3 entries
26

Brucellosis (incl. Neurobrucellosis)

C/P
  • Disabling flu-like syndrome with non-specific signs
  • Undulating ("undulant") fever, sweating, chills, myalgia, arthralgia, fatigue
  • Also known as: remitting/relapsing fever, undulant fever, Mediterranean fever
  • Common symptoms: headache, cyclical fever, migratory arthralgia, myalgia, asthenia, anorexia, fatigue, malaise, weakness, sweating, vomiting, diarrhoea, abdominal pain, miscarriage
  • Physical: may be normal; lymphadenopathy, splenomegaly, hepatomegaly
  • Skin lesions: maculopapular eruptions, erythema nodosum, abscesses
  • Ocular: uveitis, keratoconjunctivitis, iridocyclitis, optic neuritis, cataracts
  • Neurological (neurobrucellosis): meningitis (nuchal rigidity, Kernig, Brudzinski), papilloedema, cranial nerve palsy, focal neurological deficits
  • Complications (rare if treated <1 month from symptom onset):
    • Cardiovascular: endocarditis (new/changing murmurs), myocarditis, pericarditis (rub)
    • Genitourinary: orchitis, epididymo-orchitis, glomerulonephritis, pyelonephritis, abortion
    • CNS: meningitis, meningoencephalitis, papilledema, stroke, optic neuropathy
    • Haematologic: DIC
    • Musculoskeletal: sacroiliitis, arthritis, osteomyelitis, tenosynovitis
    • GI/Hepatobiliary: hepatitis, hepatic abscess, acute cholecystitis, ileitis, colitis; abscess in spinal cord, spleen, thyroid
Inves
  • Dietary + occupational history essential
  • CBC: neutropenia + anaemia; thrombocytopenia (hepatosplenomegaly or immune)
  • Raised ESR, CRP, LDH
  • Elevated ALT, AST, ALK PHOS
  • Culture (gold standard): blood culture in tryptose medium + BACTEC system; slow-growing ≥1 week; sensitivity 10–90%
  • Bone marrow culture: higher yield than blood (RES concentration)
  • Serology (most practical): Standard Agglutination Test (SAT); indirect ELISA; repeat if initial titre low
    • Titre >1:160 + compatible clinical picture → suggestive of infection
    • Titre >1:320 → more specific (esp. endemic areas)
  • PCR / NAAT: rapid, species-specific
  • Radiography (spondylitis): disc space narrowing, bone destruction, sclerosis
  • Bone marrow aspiration/biopsy: in selected patients
  • Percutaneous liver biopsy: for liver granulomas — granulomatous hepatitis, hepatic microabscesses
  • Neurobrucellosis: CSF — lymphocytes, low glucose, elevated protein (aseptic meningitis pattern); Brucella antibodies in CSF; SAT positive
  • Neurobrucellosis CSF: absence of neutrophils excludes bacterial (meningococcal) meningitis
Mng
  • Doxycycline + (streptomycin OR rifampin OR gentamicin) OR sulfamethoxazole/trimethoprim
  • Several weeks needed (intracellular organism)
  • Avoid single-agent therapy (high relapse)
  • Uncomplicated: doxycycline 100 mg PO BD × 6 weeks; monotherapy relapse ≈40% so usually + rifampin 600–900 mg/day
  • Fluoroquinolones = secondary alternatives
  • Pregnancy: rifampin during pregnancy; trimethoprim–sulfamethoxazole added postpartum
  • Spondylitis / sacroiliitis: doxycycline + rifampin + aminoglycoside (gentamicin) × 2–3 weeks initial, then 6 weeks rifampin + doxycycline
  • Symptomatic: antipyretics + analgesics
  • Surgery: endocarditis (valve replacement); drainage of pyogenic joint effusion/paraspinal abscess; debridement + bone grafting for spondylitis
  • Mostly outpatient unless complicated
  • Avoid contact with source
  • Serological monitoring during treatment
  • Compliance essential
Prevention
  • Avoid infected animals; gloves + masks; avoid contaminated food
  • Adequate cooking of meat; pasteurisation of dairy
  • Lab containment
  • Livestock vaccination (most efficient approach)
  • No human vaccine available
Special
  • Endemic zoonotic disease (cattle, dogs, sheep, goats)
  • Gram-negative aerobic coccobacillus; does NOT form spores or toxins
  • 4 human pathogenic species: B. melitensis (sheep, most virulent), B. suis (pigs, next), B. abortus (cattle), B. canis (dogs)
  • Bacteria in animal reproductive organs → abortions and sterility; shed in urine, milk, placental fluid
  • Transmission: direct animal contact; raw/unpasteurised dairy; inhalation in slaughterhouse/meat processing; butchers, lab workers high risk
  • Lacks classical virulence factors; pathogenesis via host cell invasion, immune evasion, chronic infection within macrophages
  • Incubation 3 days to several weeks
  • Relapse 5–15% within 6–12 months of completing therapy
  • Recovery 3–6 months
  • Overall mortality <2%
  • Poor prognosis with CHF due to endocarditis
  • Improves with physical activity rather than bed rest
physiology · background · low-yield
Microbiology
  • Highly infectious: as few as 10–100 organisms can cause human disease
Epidemiology/Risk
  • Most vulnerable occupational groups: slaughterhouse workers, veterinarians, farmers, laboratory technicians
Mechanism
  • Pathogenesis: ingested organisms phagocytosed → intestinal submucosa → carried to lymphoid tissue by macrophages → contained within PMNs/macrophages (avoid bactericidal responses) → spread via lymphatics; may replicate in liver, spleen, kidney, breast tissue, joints
  • Immune-evasion strategies: inhibiting phagocytosis, reducing bactericidal activity, diminishing endotoxic reactions, impeding antigen presentation
Other
  • Causes of relapse: insufficient antibiotic treatment (short duration or nonadherence); localised areas of infection
27

Brucellosis

C/P
  • Pulmonary complications: bronchitis, bronchopneumonia, hilar lymphadenopathy, lung abscess, pleural effusion
  • GI (additional to hepatitis/hepatic abscess/cholecystitis/ileitis/colitis): pancreatitis, primary bacterial peritonitis
  • CNS (additional to meningitis/meningoencephalitis/papilledema/stroke/optic neuropathy): encephalitis, psychosis, polyradiculitis, peripheral neuropathy
  • Cutaneous: vasculitis (alongside erythema nodosum, maculopapular eruptions, abscesses)
  • Genitourinary (additional): interstitial nephritis
  • Ocular (additional to uveitis/keratoconjunctivitis/iridocyclitis/optic neuritis/cataracts): keratitis, corneal ulcer, endophthalmitis
Inves
  • PCR: species-specific, detects Brucella in blood specimens
  • NAAT (nucleic acid amplification tests): accurate and rapid
  • Radiography in spondylitis: disc-space narrowing, bone destruction, sclerosis
  • Bone marrow aspiration/biopsy: may establish diagnosis in certain patients
  • Percutaneous liver biopsy (liver-granuloma patients): granulomatous hepatitis + hepatic microabscesses
Mng
  • Prevention: gloves + masks when handling infected animals; avoid potentially contaminated foods
  • Adequate cooking of meat + pasteurization of dairy products
  • Laboratory workers maintain appropriate containment
  • Animal (livestock) vaccination = most efficient approach to prevent human infection
  • No human vaccine currently available
Special
  • Genus Brucella = 12 species; 4 human-pathogenic: B. melitensis (sheep), B. suis (pigs), B. abortus (cattle), B. canis (dogs)
  • Infectious dose: as few as 10 to 100 organisms
  • More prevalent in the young; more common in males (occupational exposure); rural areas more common
  • Humans are incidental hosts, infected through contact with animals and animal products
  • Ingested organisms phagocytosed -> enter intestinal submucosa -> transported to lymphoid tissue by macrophages -> may replicate in liver, spleen, kidney, breast tissue or joints
  • Inhibits phagocytosis, reduces bactericidal activity, diminishes endotoxic reactions, impedes antigen presentation
  • Resistant to intracellular killing -> grows in phagocytes -> spreads to spleen, liver, lymph nodes, bone marrow -> host TH1 response -> granulomas form around infection foci
  • Insufficient antibiotic treatment (shorter duration or nonadherence to regimen) and localised areas of infection
  • Differential diagnosis: EBV infectious mononucleosis, infective endocarditis, influenza, malaria, meningitis, mycoplasmal pneumonia, viral hepatitis, enteric fever, acute epididymitis, urinary tract infection
28

Neurobrucellosis

Inves
  • CSF: lymphocytes (lymphocytic pleocytosis), LOW glucose, ELEVATED protein — consistent with aseptic-meningitis pattern
  • Brucella antibodies found in the sampled spinal fluid
Special
  • Absence of neutrophils in the CSF helps exclude meningococcal (pyogenic) meningitis

Helminths & Parasites

19 entries
29

Schistosomiasis (Bilharziasis)

C/P
  • Acute (Katayama fever / "swimmer itch"): sudden fever, urticaria + angioedema, chills, myalgias, arthralgias, dry cough, diarrhoea, abdominal pain, headache; 4–8 weeks post-infection
  • Chronic: months to years post-infection
    • S. mansoni: hepatosplenomegaly + periportal fibrosis → enlarged liver/spleen → portal vein occlusion → portal hypertension with splenomegaly → portocaval shunting → GI varices
    • S. haematobium: sandy patches in urinary bladder, haematuria, bladder cancer
Inves
  • Stool / urine microscopy for eggs (implied — deck focuses on chronic features)
Mng
  • Praziquantel 20 mg/kg given immediately
  • Repeated once 4–6 hours later
  • Children >4 years and adults
Special
  • Infection with parasitic blood flukes; bisexual flukes (only flukes with separate sexes infecting humans)
  • 5 species: S. mansoni, S. haematobium, S. japonicum, S. intercalatum, S. mekongi
  • Lifecycle: eggs in faeces/urine/sputum → aquatic environment → miracidia → snail intermediate host → cercariae → penetrate definitive host (skin)
  • Prevention: avoid freshwater in endemic areas (Caribbean, S. America, Africa, Asia)
physiology · background · low-yield
Mechanism
  • Skin penetration: Schistosoma larvae are the one exception to the rule that microorganisms cannot traverse unbroken skin — they release enzymes that dissolve the adhesive proteins holding keratinocytes together
30

Enterobiasis (Pinworm)

C/P
  • Cardinal symptom: pruritus ani (perianal itch)
  • Most common helminthic infection in Western Europe
Inves
  • Clinical (implied; deck doesn't detail)
Mng
  • Mebendazole 100 mg immediate dose, then repeated
  • Treat the whole family on first occasion
  • Re-infection prevention: avoid scratching; scrub under fingernails; boil-wash or hot-iron bedding + clothing to kill eggs
Special
  • Enterobius vermicularis (pinworm / threadworm)
  • Gravid worms deposit eggs in perianal folds
  • Auto-infection by scratching → hand-to-mouth
  • Person-to-person via contaminated surfaces or food
31

Trichuriasis (Whipworm)

C/P
  • Most patients asymptomatic
  • Heavy infestation: severe GI symptoms — colitis, dysentery
  • Children: iron deficiency anaemia, growth retardation; rarely rectal prolapse from severe dysentery
Inves
  • Stool microscopy
  • FBC: eosinophilia likely
Mng
  • Albendazole 400 mg BD × 3 days (unlicensed)
  • Mebendazole 500 mg single dose (adults)
  • Mebendazole 100 mg BD × 3 days (children 1–18y)
Special
  • Trichuris trichiura (whipworm)
  • Direct nematode infection (anus → mouth, no soil)
32

Ascariasis

C/P
  • SOB, cough, abdominal pain, intestinal blockage, impaired growth
Inves
  • Microscopic stool exam; imaging
Mng
  • Self-limiting with sanitation
  • Albendazole / Mebendazole if needed
Special
  • Ascaris lumbricoides — "modified direct" nematode (faecal eggs need soil incubation)
  • Transmission: eggs in faecally contaminated food/water
33

Hookworm

C/P
  • Cough, itchy rash, abdominal pain, diarrhoea, anaemia, fatigue, impaired growth
Inves
  • Microscopic observation of eggs in stool
Mng
  • Albendazole, Mebendazole
  • Prevention: wear shoes
Special
  • Ancylostoma duodenale, Necator americanus
  • Skin-penetration nematode (larvae in soil → bare feet)
34

Strongyloidiasis

C/P
  • Often asymptomatic
  • Cough ± bloody, rash, abdominal pain, diarrhoea
  • Immunosuppressed → dissemination and fatal complications
Inves
  • Larvae in stool (microscopy)
  • Serology for antigens
Mng
  • Ivermectin (preferred)
  • Albendazole
Special
  • Strongyloides stercoralis
  • Soil-dwelling larvae penetrate skin (bare feet)
35

Trichinosis

C/P
  • Diarrhoea, abdominal cramps, fever, myalgia, headache
  • Severe → impaired coordination, breathing, heart function
Inves
  • Cysts in muscle biopsy
  • Immunoassays
Mng
  • Albendazole, Mebendazole
Special
  • Trichinella spiralis
  • From raw/undercooked pork or other meat
36

Taeniasis (Intestinal Tapeworms)

C/P
  • Asymptomatic or mild GI distress
  • Cysts in muscle / eye / brain (neurocysticercosis): headaches, seizures, death
Inves
  • Proglottids or eggs in stool
  • CT/MRI for cysts
Mng
  • Praziquantel, Niclosamide
Special
  • Taenia solium, T. saginata, Diphyllobothrium latum
  • Transmission: raw/undercooked beef or pork with larvae
37

Cysticercosis

C/P
  • Cysts in lungs, liver, brain, other tissues
  • Seizures, meningitis, hydrocephalus
Inves
  • CT or MRI to detect cysts
Mng
  • Surgical removal if accessible
  • Albendazole, Praziquantel
Special
  • Taenia solium larval cysts (egg exposure via faecally contaminated food/water — distinct from taeniasis which is larvae in meat)
38

Liver Fluke Infections

C/P
  • Often asymptomatic
  • Chronic: abdominal pain, cholangitis, gallstones
Inves
  • Microscopic eggs in stool
Mng
  • Praziquantel
Special
  • Clonorchis sinensis, Opisthorchis spp.
  • Transmission: raw/undercooked freshwater fish
39

Fascioliasis

C/P
  • Diarrhoea, abdominal pain, hepatomegaly, allergic reactions
Inves
  • Microscopic eggs in stool
Mng
  • Praziquantel
Special
  • Fasciola hepatica (classed as intestinal fluke in deck)
  • Transmission: raw/undercooked aquatic plants with cysts
40

Cystic Echinococcosis (Hydatid disease)

C/P
  • cysts in lungs, liver and other organs
  • nausea, GI distress, weight loss
  • severe anaphylaxis or death if cysts burst
Inves
  • imaging
  • serologic testing — ELISA + indirect haemagglutinin test
Mng
  • surgical removal or aspiration of cysts
  • or chemotherapy with albendazole or mebendazole
Special
  • exposure to eggs in feces of infected dogs or livestock
  • cystic cestode (tissue tapeworm), Echinococcus granulosus
41

Paragonimiasis (Lung fluke)

Special
  • Paragonimus westermani — the lung fluke on the 'Common Flukes' table
  • tissue trematode; named only at survey level — no clinical detail given in the lecture
42

Fasciolopsiasis (intestinal fluke)

C/P
  • diarrhoea, abdominal pain
  • severe cases: vomiting, nausea, intestinal obstruction, anaemia, allergic reactions
Inves
  • microscopic examination of eggs in stool or other samples
  • immunoassays
Mng
  • praziquantel
Special
  • eating raw or undercooked aquatic plants containing cysts
  • distinct intestinal fluke (Fasciolopsis buski) — carries the intestinal-obstruction picture; not the liver fluke Fasciola
43

Tissue & minor helminths (named in taxonomy only)

Special
  • tissue nematodes: Onchocerca, Brugia, Wuchereria, Dracunculus, Loa loa, Toxocara
  • intestinal flukes (trematodes): Heterophyes heterophyes, Metagonimus yokogawai
  • tissue cestode: Coenurosis
  • named in the PDF taxonomy only — no clinical detail taught
44

Enterobiasis (Pinworm / Oxyuris vermicularis)

C/P
  • pruritus ani (itching around the anus)
  • abdominal pain
  • insomnia
  • irritation of the female genital tract
Inves
  • observation of eggs or worms from the anal area
  • examination of samples under fingernails
Mng
  • mebendazole (100mg immediate dose, repeated) — treatment of choice
  • albendazole
  • pyrantel pamoate
  • treat the whole family on the first occasion; boil-wash / hot-iron bedding and clothing
Special
  • enterobiasis — Enterobius vermicularis (pinworm/threadworm)
  • gravid worms deposit eggs in perianal folds; scratching transfers infective eggs to the mouth (faecal-oral)
45

Taeniasis & cysticercosis

C/P
  • asymptomatic or mild GI distress
  • cysticercosis: cysts in muscle, eye or brain
  • brain cysts → headaches, seizures, or death
Inves
  • observation of worm segments or microscopic eggs in stool
  • CT or MRI to detect cysts
Mng
  • praziquantel or niclosamide
Special
  • Taenia solium, Taenia saginata, Taenia asiatica, Diphyllobothrium latum
  • eating raw or undercooked beef or pork from an infected animal
46

Liver Fluke Infections (Fasciola / Clonorchis / Opisthorchis)

C/P
  • chronic phase: fever, malaise, anaemia
  • abdominal symptoms, transaminitis
  • cholangitis, cirrhosis
  • pancreatitis, cholecystitis, gallstones
Inves
  • microscopic examination of eggs in stool or other samples
  • immunoassays
Mng
  • triclabendazole (PREFERRED) for Fasciola spp.
  • praziquantel AND albendazole for C. sinensis and Opisthorchis spp.
Special
  • Fasciola hepatica, F. gigantica, Clonorchis sinensis, Opisthorchis viverrini, O. felineus
  • eating raw/undercooked aquatic plants (Fasciola spp.) or freshwater fish (Clonorchis spp.) contaminated with eggs or cysts
47

Helminthic therapy (experimental immunotherapy)

Special
  • experimental immunotherapy — treats autoimmune diseases / immune disorders by deliberate infestation with a helminth or its eggs
  • induces an anti-inflammatory TH2 response, opposing the pro-inflammatory TH1 response of autoimmune disease
  • most autoimmune disorders involve hyperactive Th1 or Th17 responses, down-regulated by helminth-driven Th2 promotion

Surgical & Nosocomial Infection

13 entries
1

Blood-borne infection definitions (Toxaemia / Bacteraemia / Septicaemia / Pyaemia / Septic shock)

Use: Classic definitions distinguishing forms of blood-borne spread of infection

  • Toxaemia = circulation of bacterial toxins (endo- or exo-) in blood causing pathological and clinical manifestations
  • Bacteraemia = transient circulation of a small number of bacteria without toxic manifestations
  • Septicaemia = circulation and multiplication of large numbers of virulent bacteria plus their toxins in the bloodstream
  • Pyaemia = circulation of septic emboli arresting in different organs causing metastatic abscesses
  • Septic shock = clinical syndrome of acute haemodynamic disturbance causing generalized dysfunction of cardiovascular homeostasis
  • Bacteraemia vs septicaemia: both have viable bacteria in blood, but septicaemia has a systemic response
2

Broad categories of antibiotics by mechanism of action

Use: Groups surgical antibiotics by how they act; anchors endotoxin vs Gram-positive equivalent

Cell-wall active agents
  • Beta-lactams: penicillins, cephalosporins, monobactams, carbapenems
  • Several combined with beta-lactamase inhibitors to broaden spectrum
Protein synthesis inhibitors (bind ribosomes)
  • Aminoglycosides, tetracyclines, linezolid, clindamycin
Nucleic-acid disruptors
  • Fluoroquinolones; metronidazole; trimethoprim-sulfamethoxazole
Cell-wall products
  • Endotoxin = LPS (Gram-negative); lipoteichoic acid = Gram-positive equivalent
3

Antibiotics in surgery: organism-specific therapy (first choice / alternative)

Use: First-line and alternative agents per surgical pathogen

Gram-positive
  • MSSA: flucloxacillin / clarithromycin
  • MRSA: vancomycin / linezolid / daptomycin
  • Coagulase-negative staph: vancomycin
  • S. pneumoniae and S. pyogenes: benzylpenicillin (pyogenes +/- clindamycin)
  • Enterococci: amoxicillin / vancomycin
Gram-negative / anaerobes
  • Bacteroides: metronidazole / co-amoxiclav
  • E. coli sepsis: piperacillin-tazobactam / meropenem; UTI: trimethoprim
  • H. influenzae: amoxicillin
  • Klebsiella / Proteus: co-amoxiclav
  • Pseudomonas: piperacillin-tazobactam / meropenem
Clostridia
  • Clostridium: benzylpenicillin + metronidazole
  • C. difficile: stop predisposing antibiotic + metronidazole (oral vancomycin for relapse)
4

Classification of surgical infections: Community-acquired vs Nosocomial (HAI)

Use: Divides surgical infections by setting; drives organism spectrum and resistance expectations

Community-acquired
  • Active inflammatory process present before admission
  • e.g. peritonitis from perforated colonic diverticulum
Nosocomial (hospital-acquired)
  • Arises during or as a consequence of treatment
  • e.g. intraperitoneal abscess from a colonic anastomotic leak
Why the distinction matters
  • Differing spectrum of infectious disease between settings
  • Frequent immune deficiency in hospital patients
  • Higher prevalence of antibiotic-resistant organisms in hospital-acquired infection
5

Forms of local tissue death (LTD)

Use: Four morphological forms of local tissue death and their causes

Four forms
  • Sloughs
  • Gangrene
  • Sequestrum
  • Abscess
Causes
  • Bacterial exotoxin (e.g. Cl. perfringens)
  • Increased tissue tension (tissue oedema in a limited space or vein thrombosis)
6

Outcomes of host-pathogen interaction (Local vs Spread)

Use: Maps possible fates of infection into local resolution vs regional/distant spread

Local
  • Eradication: resolution OR organization and healing by fibrosis
  • Containment: suppuration leading to abscess
  • Chronicity
Spread - regional
  • Cellulitis
  • Lymphangitis and lymphadenitis
  • Thrombophlebitis
Spread - distant
  • Bacteraemia
  • Toxaemia
  • Septicaemia
  • Pyaemia with metastatic abscesses
Suppuration vs resolution vs organization
  • Resolution = regression, no evidence of tissue destruction
  • Suppuration = excessive neutrophil exudation with tissue destruction (localized = abscess; spreading = cellulitis / necrotizing soft tissue infection)
  • Organization and repair = damaged cells removed by phagocytosis, granulation tissue grows, tissue restored or fibrosed and scarred
7

Spectrum of inflammatory responses to infection

Use: Six patterns of tissue reaction to infection with representative organisms

  • Suppurative / purulent: staphylococcal pneumonia, abscess
  • Mononuclear and granulomatous: syphilis, TB
  • Cytopathic-cytoproliferative: HPV, herpesvirus
  • Tissue necrosis: Clostridium perfringens, hepatitis B
  • Chronic inflammation and scarring: chronic hepatitis leading to cirrhosis
  • No reaction (severe immune compromise): M. avium in AIDS, mucormycosis in BMT neutropenia
8

Streptococcus species classification with disease + antibiotic sensitivity

Use: Per-species Streptococcus disease associations and antibiotic sensitivity

  • S. pyogenes: upper airway and wound infections; all strains penicillin-sensitive
  • S. faecalis / Enterococcus: UTI, cholecystitis, wound; ampicillin-sensitive, cephalosporin-resistant
  • S. viridans: commensal, can cause endocarditis; penicillin-sensitive
  • S. pneumoniae: LRTI, conjunctivitis, sinusitis, meningitis, septicaemia (esp. splenectomised - encapsulated = virulent); penicillin and erythromycin sensitive
9

Routes of Microbial Infection

Use: Classifies infection by portal of entry -> major local defence -> basis for failure of that defence -> example pathogens

Skin
  • Example pathogens: S. aureus, Candida, Pseudomonas, Schistosoma
Gastrointestinal
  • Example pathogens: Vibrio, Shigella, Norovirus, C. difficile
Respiratory
  • Example pathogens: Influenza, H. influenzae, M. tuberculosis
Urogenital
  • Example pathogens: E. coli, N. gonorrhoeae, HPV
10

SOFA Score - Graded Per-Organ Thresholds (0-4)

Use: Graded 0-4 organ-dysfunction cut-offs summed to quantify organ failure in sepsis

Respiratory - PO2/FiO2 mmHg
  • 0: >=400
  • 1: <400
  • 2: <300
  • 3: <200 with respiratory support
  • 4: <100 with respiratory support
Coagulation - Platelets /mm3
  • 0: >=150,000
  • 1: <150,000
  • 2: <100,000
  • 3: <50,000
  • 4: <20,000
Liver - Bilirubin mg/dL
  • 0: <1.2
  • 1: 1.2-1.9
  • 2: 2.0-5.9
  • 3: 6.0-11.9
  • 4: >12.0
Cardiovascular (vasopressor dose ug/kg/min)
  • 0: MAP >=70 mmHg
  • 1: MAP <70 mmHg
  • 2: dopamine <5 or dobutamine (any dose)
  • 3: dopamine 5.1-15 or norepinephrine <=0.1
  • 4: dopamine >15 or norepinephrine >0.1
CNS - Glasgow Coma Scale
  • 0: 15
  • 1: 13-14
  • 2: 10-12
  • 3: 6-9
  • 4: <6
Renal - Creatinine mg/dL (urine ml/d)
  • 0: <1.2
  • 1: 1.2-1.9
  • 2: 2.0-3.4
  • 3: 3.5-4.9 (urine <500)
  • 4: >5.0 (urine <200)
11

Classification of health care-associated infection (HAI) - 4 main groups

Use: Organising framework for infection following surgery or hospital admission

  • Respiratory infections (including ventilator-associated pneumonia, VAP)
  • Urinary tract infections (mostly urinary catheter-related)
  • Bacteraemia (mostly indwelling vascular catheter-related)
  • Surgical site infection (SSI)
12

Antibiotic classification by mechanism of action

Use: Classify agents by target and spectrum to guide empirical selection

By mechanism (3 broad categories)
  • Cell-wall active agents - beta-lactams
  • Protein-synthesis inhibitors - aminoglycosides, tetracyclines, linezolid, clindamycin
  • Nucleic-acid disruptors - fluoroquinolones, metronidazole, TMP-SMX
Empirical spectrum - targeted-spectrum
  • Gram-positive: glycopeptide / lipopeptide / oxazolidinone
  • Gram-negative: 3rd-gen cephalosporin, monobactam, polymyxins
  • Anti-anaerobic: metronidazole
Empirical spectrum - broad-spectrum & special
  • Broad-spectrum: pip-tazo, carbapenems, fluoroquinolones, tigecycline
  • Plus antipseudomonal and anti-MRSA agent lists
13

Surgical wound contamination classes + NNIS risk index

Use: Predict SSI risk from degree of contamination plus patient/operative factors

Wound classes (infection rate; worked examples)
  • Clean (class I) 2.1% - hernia repair, breast biopsy
  • Clean-contaminated (class II) 3.3% - cholecystectomy, elective GI surgery
  • Contaminated (class III) 6.4% - bowel injury from trauma / inadvertent enterotomy
  • Dirty (class IV) 7.1% - perforated appendicitis, diverticulitis, NSTI
NNIS risk index components
  • ASA score higher than 2
  • Class III or IV wound
  • Operative duration greater than the 75th percentile for that procedure

Parasitology

3 entries
14

Helminth classification scheme (shape → residence)

Use: Classify any helminth by body shape, then by residing host organ

Nematoda (roundworms) — Nematodes
  • Tissue: Onchocerca, Brugia, Wuchereria, Dracunculus, Loa loa, Trichinella, Toxocara
  • GI: Ascaris, Strongyloides, Trichuris, Enterobius, Hookworms, Trichinella
Platyhelminthes (flatworms) — Trematodes (flukes)
  • Tissue: Schistosoma, Paragonimus, Fasciola
  • GI: Clonorchis, Opisthorchis, Fasciola, Heterophyes
Platyhelminthes (flatworms) — Cestodes (tapeworms)
  • Tissue: Echinococcus, Cysticercosis, Coenurosis
  • Intestinal: Taenia saginata, Taenia solium, Diphyllobothrium latum, Hymenolepis nana
15

Nematode infection-mode classification

Use: Classify roundworms (nematodes) by their route of infection

  • Direct (anus to mouth, no soil): Enterobius vermicularis, Trichuris trichiura
  • Modified direct (eggs must incubate in soil first): Ascaris lumbricoides
  • Skin penetration: hookworms — Ancylostoma duodenale, Necator americanus
16

Fluke residence-site classification ('Common Flukes')

Use: Organise trematodes (flukes) by the organ they inhabit

  • Lung: Paragonimus westermani
  • Intestine: Fasciolopsis buski, Heterophyes heterophyes, Metagonimus yokogawai
  • Liver: Clonorchis sinensis, Opisthorchis species, Fasciola hepatica
  • Blood: Schistosoma mansoni, Schistosoma haematobium, Schistosoma japonicum

Infectious Disease

2 entries
17

WHO Definition of Severe Falciparum Malaria

Use: Diagnostic thresholds defining severe malaria - one or more of the following occurring with P. falciparum parasitemia in the absence of an identified alternative cause

  • Impaired consciousness: GCS <11 in adults or Blantyre coma score <3 in children; inability to swallow
  • Prostration: generalized weakness - unable to sit, stand or walk without assistance
  • Multiple convulsions: more than 2 episodes within 24 hours
  • Acidosis: base deficit >8 mEq/L, plasma bicarbonate <15 mmol/L, or venous plasma lactate >=5 mmol/L (rapid, deep, labored breathing)
  • Hypoglycemia: glucose <40 mg/dL (<2.2 mmol/L) for children >=5y and adults; <54 mg/dL (<3 mmol/L) for children <5y
  • Severe anemia: Hb <=5 g/dL or Hct <=15% in children <12y (<7 g/dL and <20% in adults) with parasite count >10,000/mcL (0.2% parasitemia)
  • Renal impairment: creatinine >3 mg/dL (265 mcmol/L) or blood urea >20 mmol/L
  • Jaundice: bilirubin >50 mcmol/L (3 mg/dL) with parasite count >100,000/mcL
  • Pulmonary edema: radiographically confirmed, or O2 saturation <92% on room air with respiratory rate >30/min (often chest indrawing and crepitation)
  • Significant bleeding: recurrent/prolonged bleeding (nose, gums, venipuncture sites), hematemesis, or melena
  • Shock: compensated = capillary refill >=3s or temperature gradient on leg (mid-to-proximal limb) but no hypotension; decompensated = SBP <70 mmHg in children or <80 mmHg in adults with impaired perfusion (cool peripheries / prolonged capillary refill)
  • Hyperparasitemia: P. falciparum parasitemia >10% (>500,000/mcL)
18

Traveler's Malaria Chemoprophylaxis - Drug Regimens

Use: Per-drug prophylaxis regimens - target areas, timing, adult dose, pregnancy safety and contraindications

Atovaquone-proguanil (ATV/PGN)
  • Areas: all malarious areas
  • Timing: start 1 day before entering, continue up to 7 days after leaving
  • Adult dose: 250/100 mg daily orally
  • Pregnancy: not recommended
  • Contraindications: hypersensitivity, severe renal impairment (creatinine clearance <30 mL/min), children <11 kg
Chloroquine (CLQ)
  • Areas: P. vivax, P. ovale, P. malariae and chloroquine-sensitive P. falciparum areas
  • Timing: start 1 week before entering, continue up to 4 weeks after leaving
  • Adult dose: 300 mg base weekly
  • Pregnancy: recommended (safe)
  • Contraindications: hypersensitivity, epilepsy, psoriasis, retinal diseases, severe hepatic failure
Doxycycline (DOXY)
  • Areas: all malarious areas
  • Timing: start 1 day before entering, continue up to 4 weeks after leaving
  • Adult dose: 100 mg daily
  • Pregnancy: not recommended
  • Contraindications: cutaneous hypersensitivity, hepatic diseases, tetracycline hypersensitivity, children <8 years
Mefloquine (MFQ)
  • Areas: mefloquine-sensitive malaria areas
  • Timing: start 1 week before entering (preferably 2-3 weeks), continue up to 4 weeks after leaving
  • Adult dose: 250 mg base (1 tab) weekly
  • Pregnancy: not recommended in first trimester; not <5 kg (lack of data)
  • Contraindications: hypersensitivity, seizures, psychiatric disorders, cardiac conduction abnormalities